Business Context and Reporting Period
This Form 8-K is filed by Graphite Bio, Inc. (not LENZ Therapeutics, Inc.) on March 21, 2022. The filing serves to announce the company's financial results for the fiscal year ended December 31, 2021, as detailed in the accompanying press release (Exhibit 99.1). The company is an emerging growth company incorporated in Delaware and trades on the Nasdaq Global Market under the symbol GRPH.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data for revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being contained within the press release furnished as Exhibit 99.1, which is not included in the input text.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It only confirms the issuance of a press release covering fourth-quarter and full-year 2021 results and business progress.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in this report and the accompanying exhibit shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into any other SEC filings. No specific guidance, outlook, or risk factors are detailed in the text of this Form 8-K.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in the Exhibit 99.1 Press Release referenced in this filing.
- Confirm the company name is Graphite Bio, Inc., as the metadata request incorrectly listed LENZ Therapeutics, Inc.
- Review the "Business Progress" section of the press release for updates on clinical trials or pipeline developments not detailed in this summary.
- Check the company's status as an emerging growth company for potential differences in financial reporting standards.